NCT00335829View on ClinicalTrials.gov

Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

February 28, 2011

Study Completion Date

February 28, 2011

Conditions
Liver Cancer
Interventions
BIOLOGICAL

bevacizumab

DRUG

chemotherapy

DRUG

embolization therapy

PROCEDURE

hepatic artery infusion

Trial Locations (1)

21231-2410

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Northwestern University

OTHER

lead

Yale University

OTHER

NCT00335829 - Bevacizumab and Chemoembolization in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery | Biotech Hunter | Biotech Hunter